Cargando…
The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
Autores principales: | Dovedi, Simon, Adlard, Amy, Lipowska-Bhalla, Grazyna, McKenna, Conor, Jones, Sherrie, Cheadle, Eleanor, Stratford, Ian, Poon, Edmund, Morrow, Michelle, Stewart, Ross, Jones, Hazel, Wilkinson, Robert W, Honeychurch, Jamie, Illidge, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288374/ http://dx.doi.org/10.1186/2051-1426-2-S3-O9 |
Ejemplares similares
-
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
por: Cheadle, E J, et al.
Publicado: (2017) -
Erratum: A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
por: Cheadle, E J, et al.
Publicado: (2017) -
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
por: Dovedi, Simon J., et al.
Publicado: (2016) -
A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
por: Adlard, Amy L, et al.
Publicado: (2014) -
Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations
por: Colton, Madyson, et al.
Publicado: (2020)